Journal of Korean Academy of Nursing (대한간호학회지)

Korean Society of Nursing Science (한국간호과학회)
권호 표지
DOI QR코드

DOI QR Code

Heart Rate Variability and Metabolic Syndrome in Hospitalized Patients with Schizophrenia

  • Received : 2011.05.31
  • Accepted : 2011.12.19
  • Published : 2011.12.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Reduced heart rate variability significantly increases cardiovascular mortality. Metabolic syndrome increases the cardiac autonomic dysfunction. Recently, increasing cardiovascular mortality has been reported in patients with schizophrenia. This study was done to compare heart rate variability between adults with and without schizophrenia and to compare the relationship of heart rate variability to metabolic syndrome in hospitalized patients with schizophrenia. Methods: This was a descriptive and correlational study in which 719 adults without schizophrenia and 308 adults with schizophrenia took part between May and June 2008. We measured the following: five-minute heart rate variability; high-frequency, low-frequency, the ratio of low-frequency to high-frequency, and the Standard Deviation of all the normal RR intervals. Data was also collected on metabolic syndrome, abdominal obesity, triglycerides, HDL cholesterol, blood pressure and fasting glucose. Results: The Standard Deviation of all the normal RR intervals values of heart rate variability indices were $1.53{\pm}0.18$. The low-frequency and high-frequency values of heart rate variability indices were significantly higher in hospitalized patients with schizophrenia ($3.89{\pm}1.36$; $3.80{\pm}1.20$) than those in the healthy participants ($2.20{\pm}0.46$; $2.10{\pm}0.46$). There were no significant differences between the schizophrenic patients with and without metabolic syndrome. Conclusion: The results of this study indicate that schizophrenia patients have significantly lower cardiac autonomic control, but they have significantly higher low-frequency and high-frequency values than those of healthy adults. Use of antipsychotic drug may affect the autonomic nervous system in schizophrenic patients. Metabolic syndrome was not associated with cardiac autonomic control in schizophrenia patients.

Keywords

References

  1. Agelink, M. W., Majewski, T., Wurthmann, C., Lukas, K., Ullrich, H., Linka, T., et al. (2001). Effects of newer atypical antipsychotics on autonomic neurocardiac function: A comparison between amisulpride, olanzapine, sertindole, and clozapine. Journal of Clinical Psychopharmacology, 21, 8-13. https://doi.org/10.1097/00004714-200102000-00003
  2. Astrup, A. S., Tarnow, L., Rossing, P., Hansen, B. V., Hilsted, J., & Parving, H. H. (2006). Cardiac autonomic neuropathy predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care, 29, 334-339. doi: 10.2337/diacare.29.02.06.dc05-1242
  3. Bar, K. J., Letzsch, A., Jochum, T., Wagner, G., Greiner, W., & Sauer, H. (2005). Loss of efferent vagal activity in acute schizophrenia. Journal of Psychiatric Research, 39, 519-527. https://doi.org/10.1016/j.jpsychires.2004.12.007
  4. Birkhofer, A., Alger, P., Schmid, G., & Forstl, H. (2007). The cardiovascular risk of schizophrenic patients. Neuropsychiatry, 21, 261-266.
  5. Boettger, S., Hoyer, D., Falkenhahn, K., Kaatz, M., Yeragani, V. K., & Bar, K. J. (2006). Altered diurnal autonomic variation and reduced vagal information flow in acute schizophrenia. Clinical Neurophysiology, 117, 2715-2722. doi: 10.1016/j.clinph.2006.08.009
  6. Cohen, H., Loewenthal, U., Matar, M., & Kotler, M. (2001). Association of autonomic dysfunction and clozapine. Heart rate variability and risk for sudden death in patients with schizophrenia on long-term psychotropic medication. The British Journal of Psychiatry, 179, 167-171. https://doi.org/10.1192/bjp.179.2.167
  7. Grundy, S. M., Cleeman, J. I., Merz, C. N., Brewer, H. B. Jr., Clark, L. T., Hunninghake, D. B., et al. (2004). Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation, 110, 227-239. https://doi.org/10.1161/01.CIR.0000133317.49796.0E
  8. Henry, B. L., Minassian, A., Paulus, M. P., Geyer, M. A., & Perry, W. (2010). Heart rate variability in bipolar mania and schizophrenia. Journal of Psychiatric Research, 44, 168-176. doi: 10.1016/j.jpsychires.2009.07.011
  9. Ikawa, M., Tabuse, H., Ueno, S., Urano, T., Sekiya, M., & Murakami, T. (2001). Effects of combination psychotropic drug treatment on heart rate variability in psychiatric patients. Psychiatry and Clinical Neurosciences, 55, 341-345. doi: 10.1046/j.1440-1819.2001.00873.x
  10. Karason, K., Molgaard, H., Wikstrand, J., & Sjostrom, L. (1999). Heart rate variability in obesity and the effect of weight loss. American Journal of Cardiology, 83, 1242-1247. doi: 10.1016/S0002-9149(99)00066-1
  11. Kelly, D. L., McMahon, R. P., Liu, F., Love, R. C., Wehring, H. J., Shim, J. C., et al. (2010). Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: A retrospective cohort study. Journal of Clinical Psychiatry, 71, 304-311. doi: 10.4088/JCP.08m04718yel
  12. Kim, J. A., Park, Y. G., Cho, K. H., Hong, M. H., Han, H. C., Choi, Y. S., et al. (2005). Heart rate variability and obesity indices: Emphasis on the response to noise and standing. Journal of the American Board of Family Practice, 18, 97-103. doi: 10.1152/japplphysiol.01275.2005
  13. Kuch, B., Hense, H. W., Sinnreich, R., Kark, J. D., von Eckardstein, A., Sapoznikov, D., et al. (2001). Determinants of short-period heart rate variability in the general population. Cardiology, 95, 131-138. https://doi.org/10.1159/000047359
  14. Kudat, H., Akkaya, V., Sozen, A. B., Salman, S., Demirel, S., Ozcan, M., et al. (2006). Heart rate variability in diabetes patients. Journal of International Medical Research, 34, 291-296. https://doi.org/10.1177/147323000603400308
  15. La Rovere, M. T., Bigger, J. T. Jr., Marcus, F. I., Mortara, A., & Schwartz, P. J. (1998). Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet, 351, 478-484. doi: 10.1016/S0140-6736(97)11144-8
  16. La Rovere, M. T., Pinna, G. D., Hohnloser, S. H., Marcus, F. I., Mortara, A., Nohara, R., et al. (2001). Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: Implications for clinical trials. Circulation, 103, 2072-2077. https://doi.org/10.1161/01.CIR.103.16.2072
  17. Lee, W. Y., Park, J. S., Noh, S. Y., Rhee, E. J., Kim, S. W., & Zimmet, P. Z. (2004). Prevalence of the metabolic syndrome among 40,698 Korean metropolitan subjects. Diabetes Research and Clinical Practice, 65, 143-149. https://doi.org/10.1016/j.diabres.2003.12.007
  18. Liao, D., Carnethon, M., Evans, G. W., Cascio, W. E., & Heiss, G. (2002). Lower heart rate variability is associated with the development of coronary heart disease in individuals with diabetes: The atherosclerosis risk in communities (ARIC) study. Diabetes, 51, 3524-3531. https://doi.org/10.2337/diabetes.51.12.3524
  19. Mann, K., Rossbach, W., Muller, M. J., Muller-Siecheneder, F., Ru, H., & Dittmann, R. W. (2004). Heart rate variability during sleep in patients with schizophrenia treated with olanzapine. International Clinical Psychopharmacology, 19, 325-330. https://doi.org/10.1097/00004850-200411000-00002
  20. McEvoy, J. P., Meyer, J. M., Goff, D. C., Nasrallah, H. A., Davis, S. M., Sullivan, L., et al. (2005). Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research, 80, 19-32. doi: 10.1016/j.schres.2005.07.014
  21. Meyer, J. M. (2001). Effects of atypical antipsychotics on weight and serum lipid levels. Journal of Clinical Psychiatry, 62, 27-34.
  22. Meyer, J. M., Nasrallah, H. A., McEvoy, J. P., Goff, D. C., Davis, S. M., Chakos, M., et al. (2005). The Clinical Antipsychotic trials Of Intervention Effectiveness (CATIE) Schizophrenia trial: Clinical comparison of subgroups with and without the metabolic syndrome. Schizophrenia Research, 80, 9-18. doi: 10.1016/j.schres.2005.07.015
  23. Montano, N., Gneddhi, R.T., Porta, A., Lombardi, F., Pagani, M., & Malliani, A. (1994). Power spectrum analysis of heart rate variability to assess the changes in sympathovagal balance during graded orthostatic tilt. Circulation, 90, 1826-1831. https://doi.org/10.1161/01.CIR.90.4.1826
  24. Oh, J. Y., Hong, Y. S., Sung, Y. A., & Barrett-Connor, E. (2004). Prevalence and factor analysis of metabolic syndrome in an urban Korean population. Diabetes Care, 27, 2027-2032. doi: 10.2337/diacare.27.8.2027
  25. Sugawara, N., Yasui-Furukori, N., Sato, Y., Kishida, I., Yamashita, H., Saito, M., et al. (2011). Comparison of prevalence of metabolic syndrome in hospital and community-based Japanese patients with schizophrenia. Annals of General Psychiatry, 10(21), 1-8. doi: 10.1186/1744-859X-10-21
  26. Suvisaari, J. M., Saarni, S. I., Perala, J., Suvisaari, J. V., Harkanen, T., Lonnqvist, et al. (2007). Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey. Journal of Clinical Psychiatry, 68, 1045-1055. https://doi.org/10.4088/JCP.v68n0711
  27. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. (1996). Heart rate variability: Standards of measurement, physiological interpretation, and clinical use. Circulation, 93, 1129-1136.
  28. Van Ravenswaaij-Arts, C. M., Kollee, L. A., Hopman, J. C., Stoelinga, G. B., & van Geijn, H. P. (1993). Heart rate variability. Annals of Internal Medicine, 118, 436-447. https://doi.org/10.7326/0003-4819-118-6-199303150-00008
  29. WHO, IASO, & IOTF. (2000). The Asia-Pacific perspective: Redefining obesity and its treatment. Australia: Health Communications, 1-56.
  30. Wang, Y. C., Yang, C. C., Bai, Y. M., & Kuo, T. B. (2008). Heart rate variability in schizophrenic patients switched from typical antipsychotic agents to amisulpride and olanzapine: 3-month follow-up. Neuropsychobiology, 57, 200-205. doi: 10.1159/000149818

Cited by

  1. Metabolic syndrome in schizophrenia vol.35, pp.3, 2011, https://doi.org/10.4103/0253-7176.119471
  2. Evaluation of autonomic nervous system by salivary alpha-amylase level and heart rate variability in patients with schizophrenia vol.264, pp.1, 2014, https://doi.org/10.1007/s00406-013-0411-6
  3. Heart rate variability and the metabolic syndrome: a systematic review of the literature vol.30, pp.8, 2011, https://doi.org/10.1002/dmrr.2555
  4. Resting vagal activity in schizophrenia: meta-analysis of heart rate variability as a potential endophenotype vol.208, pp.1, 2011, https://doi.org/10.1192/bjp.bp.114.160762
  5. Factors Influencing Metabolic Syndrome among Mental Health Facility Patients with Schizophrenia vol.25, pp.1, 2011, https://doi.org/10.12934/jkpmhn.2016.25.1.1
  6. Impact of metabolic syndrome and its components on heart rate variability during hemodialysis: a cross-sectional study vol.15, pp.None, 2011, https://doi.org/10.1186/s12933-016-0328-2
  7. Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health vol.7, pp.1, 2021, https://doi.org/10.1038/s41537-021-00151-6